1. Home
  2. FTCI vs ALXO Comparison

FTCI vs ALXO Comparison

Compare FTCI & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo FTC Solar Inc.

FTCI

FTC Solar Inc.

HOLD

Current Price

$8.93

Market Cap

93.0M

Sector

Technology

ML Signal

HOLD

Logo ALX Oncology Holdings Inc.

ALXO

ALX Oncology Holdings Inc.

HOLD

Current Price

$1.33

Market Cap

79.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTCI
ALXO
Founded
2017
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Semiconductors
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
93.0M
79.7M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
FTCI
ALXO
Price
$8.93
$1.33
Analyst Decision
Buy
Strong Buy
Analyst Count
4
6
Target Price
$6.63
$3.30
AVG Volume (30 Days)
421.4K
341.3K
Earning Date
11-12-2025
11-07-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$80,028,000.00
N/A
Revenue This Year
$93.79
N/A
Revenue Next Year
$165.11
N/A
P/E Ratio
N/A
N/A
Revenue Growth
39.53
N/A
52 Week Low
$2.13
$0.40
52 Week High
$11.45
$2.27

Technical Indicators

Market Signals
Indicator
FTCI
ALXO
Relative Strength Index (RSI) 52.09 45.25
Support Level $8.10 $1.29
Resistance Level $9.70 $1.56
Average True Range (ATR) 1.00 0.15
MACD -0.04 -0.00
Stochastic Oscillator 46.15 34.63

Price Performance

Historical Comparison
FTCI
ALXO

About FTCI FTC Solar Inc.

FTC Solar Inc is a provider of solar tracker systems, supported by proprietary software and value-added engineering services. The company's Solar tracker systems move solar panels throughout the day to maintain an optimal orientation relative to the sun, thereby increasing the amount of solar energy produced at a solar installation. It focuses on providing differentiated products, software, and services that maximize energy generation. The company has launched a new mounting solution to support the installation and use of U.S. manufactured thin-film modules by project owners. The only segment the company is engaged in is the Manufacturing and Servicing of Solar tracker systems.

About ALXO ALX Oncology Holdings Inc.

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Share on Social Networks: